ProSomnus 510(k) Submission Under Review for Severe Indication
The FDA is in the process of reviewing ProSomnus' premarket notification for its ProSomnus EVO oral appliance for severe sleep apnea.
Source: sleepreviewmag.com
Stay updated with breaking news from John Remmers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA is in the process of reviewing ProSomnus' premarket notification for its ProSomnus EVO oral appliance for severe sleep apnea.
PLEASANTON, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea ("OSA"), today announced that their precision sleep apnea
ProSomnus will present new data demonstrating the efficacy of its precision oral appliances for OSA at upcoming medical conferences.